<![CDATA[NCCN Guidelines Recommend Taletrectinib for ROS1+ NSCLC Subtype]]>

Summary: Great news for people fighting a specific type of lung cancer (ROS1-positive NSCLC) that has spread to the brain. Top cancer experts at the NCCN have officially recommended a medicine called taletrectinib (Ibtrozi). In studies, this daily pill shrank brain tumors in over 76% of new patients and kept the cancer from growing for almost four years! It works well even if other treatments have stopped working. The side effects are usually mild, like an upset stomach or dizziness. Doctors are excited because this medicine easily reaches the brain to fight the cancer right where it hides.

Source: cancernetwork URL: cancernetwork.com/view/nccn-guidelines-recommend-taletrectinib-for-ros1-nsclc-subtype (opens in new tab)